Onxeo (Onxeo)

Oncology Corporate Profile

HQ Location

49 boulevard du Général Martial Valin
Paris , France 75015

Company Description

Onxeo was created through the merger of BioAlliance Pharma, a French innovative company based in Paris specializing in the development of drugs for orphan diseases in oncology, with Topotarget, a Danish biopharmaceuticals company based in Copenhagen, also a specialist in the development of oncology products.

Website: http://www.onxeo.com/en

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Livatag? / BA-003 nanoparticle doxorubicinHepatocellular carcinoma (HCC)III
Clonidine Lauriad? / BA-028 alpha 2 adrenoreceptor agonistOral mucositis with Head & Neck cancerII
AMEP? / BA-015 anti-angiogenic and anti-proliferative peptide1st line metastatic MelanomaI
Fentanyl Lauriad? / BA-041 Mu opioid receptor agonistCancer painI

View additional information on product candidates here »

Pipeline image

Source


http://www.onxeo.com/en

Recent News Headlines

Sosei announces completion of Japanese Phase III clinical study of SO-1105 for oropharyngeal candidiasis and achievement of principal endpoints

8/29/2016 06:05 am

[at noodls] - Tokyo, Japan - 29 August 2016: Sosei Group Corporation (TSE Mothers Index: 4565) hereby announces that its Japanese subsidiary Sosei Co. Ltd. has completed the Japanese Phase III study of SO-1105 (miconazole ...